1)
Vascular endothelial growth factor (VEGF)-A, also known as vascular permeability factor, is considered to play an important role in tumor angiogenesis. 2) Recently, three new members of the VEGF family, VEGF-B, -C and -D, have been discovered and characterized. [3] [4] [5] [6] It has been suggested that VEGF family members are expressed in a variety of human tumors in different ways, [7] [8] [9] [10] but their precise roles remain to be elucidated.
VEGF-C is a ligand for VEGF receptor-3 (VEGFR-3, Flt-4), a tyrosine kinase receptor which is predominantly expressed in the endothelium of lymphatic vessels. 4) Experimental results with the VEGF-C-transgenic mouse have shown that the expression of VEGF-C is associated with hyperplasia of lymphatic vessels.
11) The newest member of the VEGF family, VEGF-D, is 48% identical with VEGF-C. 5, 6) VEGF-D also can bind to and activate VEGFR-3. 6) To date, no other growth factor involved in the development of lymphatic vessels has been reported. Therefore, it is conceivable that VEGF-C and VEGF-D might play a crucial role in the development of lymphatic vessels in solid tumors.
To obtain some clue as to this role, we developed a semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) method to investigate the mRNA expression levels of the VEGF family members in breast cancer. Firstly, we investigated the expression levels of VEGF family members in seven human breast cancer cell lines and found that all the VEGF family members were expressed in cancer cells at different levels. Next, normal mammary glands and breast cancer specimens were analyzed by the same method.
MATERIALS AND METHODS

Cell lines and tumor samples
The KPL-1, KPL-3C and KPL-4 cell lines were established in our laboratory and their characterization has been reported elsewhere. [12] [13] [14] These cell lines were derived from the malignant pleural effusion of three different Japanese patients with recurrent breast cancer. The KPL-1 and KPL-3C cell lines are estrogen receptor (ER)-positive, but the KPL-4 cell line is not. Four other human breast cancer cell lines, the MCF-7 (early passage), T-47D, MDA-MB-231 and SkBr-3 cell lines were kindly provided by Dr. Robert B. Dickson (at the Lombardi Cancer Center, Georgetown University Medical Center, DC). All of the seven cell lines, except for the KPL-3C line, were routinely cultured in Dulbecco's modified Eagle's medium (ICN Biochemicals, Costa Mesa, CA) supplemented with 5% fetal bovine serum (ICN Biochemicals Japan, Osaka). KPL-3C cells were cultured in RPMI-1640 medium (GIBCO BRL, Bethesda, MD) supplemented with 5% fetal bovine serum and 1 nM phorbol-12-myristate-13-acetate (Sigma Chem. Co., St. Louis, MO).
A total of 20 breast cancer specimens were selected from the tumor bank of our department. Eight tumors were derived from patients with node-negative breast cancer, and the other 12 tumors were derived from patients with node-positive or inflammatory breast cancer. The histology of each tumor sample, particularly the grade of vascular invasion, was reviewed by a pathologist [Y. M.] according to the criteria described by Pinder et al. 15) In brief, vascular invasion was assessed in the breast tissue adjacent to the infiltrating margin of the primary tumor. In each case, sections including the largest dimension of the main tumor were examined. Both lymphatic spaces and capillary-sized small blood vessels were designated as vascular because they were indistinguishable from each other.
Additionally, to investigate the expression levels of the VEGF family members in normal mammary tissues, three normal mammary tissues were selected from the tumor bank of our department. The samples were resected from mastectomy specimens and located more than 5 cm away from breast tumors. Histologic examination of the samples revealed neither cancer tissues nor fibrocystic changes. RT-PCR analysis Total cellular RNA from the human breast cancer cell lines and breast tumor specimens was extracted with a TRIzol RNA extraction kit (GIBCO BRL Life Technologies, Gaithersburg, MD) according to the manufacturer's recommendations. One microgram of total RNA and oligo(dT) 18 primer (final concentration: 1 µM) in 12.5 µl of diethyl pyrocarbonate-treated water was heated to 70°C for 2 min followed by cooling on ice for 1 min. cDNA synthesis was initiated with 200 units of recombinant Molony-murine leukemia virus reverse transcriptase (CLONTECH Laboratories, Inc., Palo Alto, CA) under the conditions recommended by the manufacturer, and the reaction was allowed to proceed at 42°C for 1 h. The reaction was terminated by heating at 94°C for 5 min. cDNA was finally dissolved to a final volume of 100 µl by adding 80 µl of diethyl pyrocarbonate-treated water and the solution was frozen at −20°C until use. Oligonucleotide primers for RT-PCR were designed using a published sequence of each target gene and synthesized by the solidphase triester method. The primers used in this study and the expected sizes from the reported cDNA sequence are shown in Table I . Each RT-PCR reaction contained 1/100 of cDNA (equivalent to the cDNA from 10 ng of initial total RNA), 200 nM concentrations of each primer, 200 µM deoxynucleotide triphosphates, 10 mM Tris-HCl (pH 8.8), 1.5 mM MgCl 2 , 50 mM KCl, 0.08% Nonidet P40, and 1 unit of recombinant Thermus aquaticus DNA polymerase (MBI Fermentas, Vilnius, Lithuania) in a final volume of 20 µl. After an initial denaturation at 94°C for 4 min, various cycles of denaturation (94°C for 15 s), annealing (60°C for β-actin and 56-60°C for other genes for 15 s), and extension (72°C for 30 s) for the respective target genes were performed on a DNA Thermal Cycler 2400 (PC-960G Microplate Gradient Thermal Cycler, Mortlake, Australia). The final extension was performed for 5 min. The number of cycles in the RT-PCR was determined so as to obtain logarithmic amplification of each gene for semi-quantitative analysis of the expression levels of the genes (Table I) . After visualization of the RT-PCR products by 1.2% agarose gel electrophoresis with ethidium bromide staining, gel images were obtained using the FAS-II UV-image analyzer (Toyobo Co., Ltd., Tokyo), and the densities of the products were quantified using the Quantity One version 2.5 (PDI Inc., Huntington Station, NY). The relative expression levels were calculated as the density of the product of the respective target genes divided by that of β-actin from the same cDNA. Statistical analysis The relative mRNA expression levels of each VEGF family member in node-positive and -negative tumors were compared using the unpaired Student's t test. The criterion of significance was set as P<0.05.
RESULTS
Expression of mRNAs of all the VEGF family members was detected in all seven human breast cancer cell lines explored by our RT-PCR analysis, as shown in Fig. 1 . Table I . As shown in Table III VEGF-A mRNA expression but not mRNA expression of VEGF-B, -C and -D was detected in the normal mammary tissues (Table III) . The result of RT-PCR analysis of normal mammary tissues and representative tumor samples is shown in Fig. 2 .
DISCUSSION
Expression analysis using semi-quantitative RT-PCR in this study suggested a possible relationship between the expression level of VEGF-C and/or VEGF-D and the development of lymphatic tumor spread. VEGF-C expression was detectable by our RT-PCR analysis in 75% of node-positive tumors, but 0% of node-negative tumors. VEGF-D expression was detectable in 33% of inflammatory-type tumors, but 0% (0 out of 14) of other noninflammatory-type tumors. In addition, the KPL-1 cell line, which causes frequent lymphatic metastasis in nude mice, 12) expressed a higher level of VEGF-C mRNA and the KPL-4 cell line, which was derived from a patient with an inflammatory skin metastasis, 14) expressed a higher level of VEGF-D. In contrast, VEGF-A and VEGF-B, which are known to stimulate the formation of blood vessels in tumors, were expressed in most tumor samples explored regardless of nodal status.
It should be noted that our RT-PCR analysis is semiquantitative and that the protein levels of the VEGF family members were not investigated in this study. However, the expression level of each member was normalized with respect to that of a housekeeping gene, β-actin, in each sample and the relative expression levels were compared with each other. In addition, the localization of mRNA of each VEGF family member was not investigated in this study. However, it has been reported that both mRNA and the protein product of VEGF-B are localized to tumor cells and that VEGF-C mRNA is localized to tumor cells. 8) No information is available with regard to the localization of VEGF-D mRNA in tumor tissues. In addition, we have shown in this study that all seven human breast cancer cell lines explored express all the VEGF family members. These findings suggest that all the VEGF family members might be preferentially expressed in cancer cells. Further analysis is clearly needed to investigate the protein expression levels of the VEGF family members.
The grade of angiogenesis, which is expressed as the microvessel density in tumors, is reported to be a strong prognostic indicator in a variety of malignancies. 16) However, lymph node status is still the strongest prognostic factor in breast cancer. It has been speculated that lymph node metastasis is promoted by tumor cell aggressiveness, such as abilities of invasiveness, motility and proliferation. Otherwise, no specific factor that promotes lymphatic tumor cell spread has been discovered. Very recently, however, two such candidates, VEGF-C and VEGF-D, have been put forward. These factors might promote the development of lymphatic vessels in tumors and the entry of tumor cells into lymphatic vessels. Although no causative factor inducing an inflammatory skin change in breast cancer has been discovered, VEGF-C and/or VEGF-D might promote lymphatic tumor cell spread into subdermal lymphatic vessels and might induce an inflammatory skin change. Our expression analysis in the present study can- Table I .
not cast light on these hypothetical issues because the causal relationship between VEGF-C and/or -D expression and lymphatic tumor spread remains to be investigated. Neutralizing antibodies against VEGFR-3 may be useful to clarify the causal relationship and might be useful for the treatment of inflammatory-type breast cancer.
Because of a lack of methodology to recognize specifically lymphatic vessels, the precise mechanisms of the development of lymphatic vessels in tumors have not been investigated. However, monoclonal antibodies against a specific antigenic marker for lymphatic endothelial cells, VEGFR-3, to which VEGF-C and VEGF-D bind, have been produced and these monoclonal antibodies can distinguish lymphatic vessels from blood vessels. 17) Further studies on the roles of the VEGF family members using the VEGFR-3 antibodies may disclose the mechanisms of lymphatic metastasis as well as of inflammatory skin change in breast cancer.
